艾拉莫德治疗类风湿性关节炎患者的临床效果分析

Clinical effect analysis of iguratimod in the treatment of patients with rheumatoid arthritis

目的:探讨艾拉莫德治疗类风湿性关节炎患者的临床效果。方法:纳入我院80例2017.3.18～2018.2.24类风湿性关节炎患者。随机数字表分组,常规治疗组采取常规用药治疗,艾拉莫德组则采取常规用药加上艾拉莫德治疗。比较常规治疗组、艾拉莫德组疗效;晨僵症状解除时间、血沉改善30%的时间、肿胀消退时间;治疗前后患者晨僵维持时间、肿胀指数、C反应蛋白、血沉、关节疼痛指标;不良反应。结果:艾拉莫德组疗效、晨僵症状解除时间、血沉改善30%的时间、肿胀消退时间、晨僵维持时间、肿胀指数、C反应蛋白、血沉、关节疼痛指标相比较常规治疗组更好,P<0.05。艾拉莫德组不良反应和常规治疗组无明显差异,P>0.05。结论:常规用药加上艾拉莫德治疗类风湿性关节炎的效果理想。

Objective: To investigate the clinical effects of iguratimod in the treatment of patients with rheumatoid arthritis. Methods: 80 patients with rheumatoid arthritis were enrolled in our hospital from March 18 th 2017 T to February 24 th 2018. The random number table was grouped, the conventional treatment group was treated with conventional medication, and the iguratimod group was treated with conventional medication plus iguratimod. Compared with the conventional treatment group and the iguratimod group;the morning stiffness symptom relief time, the erythrocyte sedimentation rate improved by 30%, the swelling regression time;the patient’s morning stiffness maintenance time, swelling index, C-reactive protein, erythrocyte sedimentation rate, joint pain index;Adverse reactions. Results: Iguratimod group efficacy, morning stiffness relief time, erythrocyte sedimentation rate improvement time 30%, swelling regression time, morning stiffness maintenance time, swelling index, C-reactive protein, erythrocyte sedimentation rate, joint pain index were better than conventional treatment group., P < 0.05. There was no significant difference between the iguratimod group and the conventional treatment group(P > 0.05). Conclusion: Conventional medication plus iguratimod is effective in the treatment of rheumatoid arthritis.